A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)https://www.nct-dresden.de/en/trials/900-000002515https://www.nct-dresden.de/@@site-logo/logo-nct.svg
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) thatis recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC)responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) andzanzalintinib compared to cabozantinib.The goal of this study is to learn if:People who take belzutifan and zanzalintinib live longer overall and without the cancergetting worse than people who take cabozantinib.
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) thatis recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC)responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) andzanzalintinib compared to cabozantinib.The goal of this study is to learn if:People who take belzutifan and zanzalintinib live longer overall and without the cancergetting worse than people who take cabozantinib.
